Growth-hormone-derived peptide studied for effects on fat metabolism
Clinical research
Read the profile Peptide profile
Liraglutide
GLP-1 receptor agonist
Approved medicines exist
Science, with its context intact.What to knowThe evidence
The evidence
in perspective.
FDA has approved specific liraglutide products, including Saxenda for defined weight-management populations. This is product-specific evidence, not a general wellness claim.
View the supporting source- Research area
- Metabolic
- Biological target or mechanism
- GLP-1 receptor agonist
- Evidence context
- Approved medicines exist
- Availability
- Availability requires pharmacy review
From information to a conversationClinical decisions stay
Clinical decisions stay
with clinical professionals.
This profile is a research reference. Your prescriber and pharmacy assess the relevant clinical and dispensing pathway. Inclusion here is not an offer to sell this compound.
